LOS ANGELES (Reuters) - Express Scripts, the largest manager of prescription drug plans for U.S. employers, is taking an increasingly aggressive stance in price negotiations with pharmaceutical ...

Advocates for lower drug prices say a federal lawsuit filed this month against St Louis-based Express Scripts and two other companies could result in more affordable medicine for patients. The Federal ...

Praluent has a list price of more than $14,000 a year. However, Express Scripts customers will be able to receive the drug for $4,500 to $6,600 annually after discounts and rebates, Express Scripts ...

Express Scripts Holding, a pharmacy benefit manager that negotiates drug prices for many health plans, will launch a formulary with lower list price drugs in an effort to reduce reliance on rebates ...

Express Scripts ClearNetworkSM offers employers and health plans a new option for simple, "cost-plus" pharmacy pricing for brand, generic, and specialty medications. "We are constantly innovating to ...

(Reuters) - The largest U.S. pharmacy benefit manager said on Monday it has lined up a cheaper price for AbbVie Inc's newly approved hepatitis C treatment and, in most cases, will no longer cover ...

The FTC accuses major PBMs of inflating insulin prices, impacting patient costs and access to affordable medications. PBMs prioritize high-rebate drugs, contributing to high insulin prices and ...

Express Scripts, Caremark and OptumRx are suing the Federal Trade Commission for trying to "upend present day drug rebate contracts." The lawsuit was filed Tuesday, Nov. 19 in federal court in ...

Drugmakers including Purdue Pharma paid pharmacy benefit managers not to restrict painkiller prescriptions, a New York Times investigation found. By Chris Hamby New legislation would force ...

As Adam Fein of Drug Channels Institute puts it, these forces are finally puncturing the “ gross-to-net bubble ”—the vast gap ...

The case takes aim at the major pharmacy benefit managers, agency officials said, claiming that they favored more expensive insulin products and forced patients to pay more. By Reed Abelson and ...